Vraylar Patient Assistance Program: 2026 Eligibility and How to Apply

What Is the Vraylar Patient Assistance Program?

Vraylar (cariprazine) is an atypical antipsychotic approved by the FDA for schizophrenia, the acute treatment of manic or mixed episodes of bipolar I disorder, bipolar depression, and as an add-on to antidepressants for major depressive disorder (MDD) in adults. It is manufactured by AbbVie, and as a brand-only specialty medication with no generic, its retail price commonly runs well over $1,400 for a 30-day supply — among the more expensive psychiatric medications on the market. The Vraylar Patient Assistance Program is designed to help eligible patients obtain their medication at no cost when they lack adequate insurance coverage.

For patients who rely on Vraylar to manage serious mental health conditions, interruptions in treatment can have serious consequences. The Vraylar Patient Assistance Program exists specifically to keep cost from becoming a barrier to consistent care. This guide explains how to determine your eligibility, complete the application, and understand your options — but always confirm the current terms on the official myAbbVie Assist website, because program rules and dollar figures change.

This article is independent educational information, not medical advice. FMHC is not affiliated with, endorsed by, or sponsored by AbbVie, and we do not administer myAbbVie Assist.

Important Safety Information: FDA Boxed Warnings

Vraylar carries two FDA boxed warnings — the agency’s most serious type of warning. Read these before considering treatment, and discuss them with your prescriber.

• Increased mortality in elderly patients with dementia-related psychosis. Older adults with dementia-related psychosis who are treated with antipsychotic drugs face an increased risk of death. Vraylar is not approved for treating dementia-related psychosis.
• Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Because Vraylar can be used alongside an antidepressant for MDD, anyone starting treatment should be closely monitored for worsening mood or the emergence of suicidal thinking, especially in the first weeks and after dose changes.

Never start, stop, or change the dose of an antipsychotic on your own. Stopping abruptly can trigger relapse or withdrawal effects, so any change should be made only under your prescriber’s supervision. If you or someone you know is in crisis or thinking about self-harm, call or text 988 (the Suicide and Crisis Lifeline) right away, or go to the nearest emergency room.

Medications and Dosages Covered

The program covers the FDA-approved strengths of Vraylar. AbbVie manufactures the following capsule strengths, and your prescriber selects the one that is right for you:

• 1.5 mg capsules
• 3 mg capsules
• 4.5 mg capsules
• 6 mg capsules
• Vraylar titration/starter pack (containing more than one strength)

Your prescribing physician specifies the exact strength on the application form — this article does not provide dosing guidance, and you should follow only the regimen your prescriber gives you. If your prescription changes during your enrollment period, your doctor’s office can update it with AbbVie without your having to start a brand-new application from scratch.

Eligibility Requirements

The Vraylar Patient Assistance Program is administered through AbbVie’s patient assistance program, myAbbVie Assist. General eligibility criteria have historically included the following, though AbbVie updates them, so verify the current rules before you apply.

• U.S. residency: You must be a legal resident of the United States being treated by a U.S.-licensed prescriber.
• No adequate coverage: You must be uninsured, or have insurance that does not cover Vraylar (including cases where prior authorization has been denied). Some insured patients facing catastrophic out-of-pocket costs may still qualify.
• Income limits: AbbVie sets an income ceiling that for many products has reached roughly 600% of the Federal Poverty Level (FPL). For 2026, 600% of FPL is approximately $95,760 for a single-person household and about $198,000 for a family of four, based on the HHS poverty guidelines. Treat these as illustrative — the exact threshold varies by product and changes annually, so confirm the current figure for Vraylar.

Patients enrolled in Medicaid, TRICARE, or VA benefits are generally not eligible for the assistance program, though there can be exceptions — for example, patients denied coverage by a government plan. Medicare Part D patients face separate rules and may need to show they were denied the Extra Help subsidy before being evaluated. Confirm your specific situation through the official myAbbVie Assist website.

How to Apply

The application involves both the patient and the prescribing physician. Following these steps makes the process smoother.

Step 1: Obtain the Application

Download the application from the official myAbbVie Assist website, or ask your prescriber’s office to help you request one. Applications are also often available through nonprofit resources such as NeedyMeds.org and RxAssist.org.

Step 2: Complete the Patient Section

Provide your personal information, insurance status, and household income details. You will typically need proof of income, such as your most recent tax return, a Social Security award letter, or recent pay stubs.

Step 3: Physician Section

Your prescribing psychiatrist or physician completes the clinical section, including their NPI number, the Vraylar strength prescribed, and a signature confirming medical necessity. Many psychiatric practices handle myAbbVie Assist forms regularly.

Step 4: Submit the Application

Submit the completed application and income documentation by the method AbbVie specifies on the current form (secure portal, fax, or mail). Submitting a complete package the first time avoids delays.

Step 5: Wait for Processing

Applications are typically processed within a few weeks. Once approved, Vraylar is generally shipped to your physician’s office at no cost, and you pick up each supply during regular visits. Timelines vary, so confirm the current process on the official site.

Renewal and Ongoing Enrollment

Approval through the Vraylar Patient Assistance Program is generally valid for up to 12 months. Before your enrollment expires, AbbVie typically sends a renewal notice to you and your prescriber. To keep receiving medication, you must submit updated income verification and a renewed prescriber certification.

Start the renewal process early — ideally four to six weeks before your current enrollment expires — to prevent gaps in your medication supply. If your enrollment lapses, you can reapply, but processing a new application may take additional time. During enrollment, refills are usually shipped on a rolling schedule your doctor’s office coordinates with AbbVie.

Vraylar Copay Savings Card

If you have commercial (private) insurance but face high copays for Vraylar, AbbVie offers a separate copay savings card. For eligible patients, this card can substantially lower your out-of-pocket cost per fill, up to an annual maximum. The specific minimum copay and annual cap change over time, so verify the current amounts on the official Vraylar savings page rather than relying on any figure quoted elsewhere.

The copay card is not available to patients covered by Medicare, Medicaid, TRICARE, or any other government-funded program — that restriction is set by federal anti-kickback law. It is only for people with commercial insurance. You can enroll and read the full terms on the official Vraylar website.

If you are unsure whether the patient assistance program or the copay card fits your situation, AbbVie’s support team and your prescriber’s office can help you compare based on your insurance and finances.

Alternative Savings Options

If you do not qualify for the patient assistance program or the copay card, other strategies may reduce your Vraylar costs.

Discount cards: Platforms like GoodRx sometimes list Vraylar discounts, but because it is a brand-only specialty drug with no generic, the savings are usually modest, and you may still pay well over $1,000 per fill even with a card.

Medicare Extra Help: If you are a Medicare Part D beneficiary with limited income, the Extra Help (Low-Income Subsidy) program can sharply reduce your copays for covered drugs, including Vraylar. Apply through Social Security to see if you qualify.

State pharmaceutical assistance programs: Some states run programs that supplement Part D coverage or help uninsured residents afford expensive medications. Check with your state’s department of health or Medicaid office.

Therapeutic alternatives: Ask your psychiatrist whether a lower-cost atypical antipsychotic, such as generic aripiprazole or generic quetiapine, could be appropriate for you. Those generics can cost far less per month. However, psychiatric medication changes should never be made without medical supervision, and cariprazine’s specific receptor profile means it may help where other medicines have not — so this is a conversation for you and your prescriber, not a do-it-yourself switch.

Frequently Asked Questions

Is there a generic for Vraylar?

As of 2026, there is no FDA-approved generic version of Vraylar (cariprazine). AbbVie holds patent protections, and broad generic entry is not expected in the near term. When a generic eventually arrives, the price is expected to fall substantially. Visit our generic vs. brand name drugs guide for more on how generics work.

Can Medicare patients use the Vraylar Patient Assistance Program?

Medicare Part D patients may qualify in specific circumstances, particularly if they face high cost-sharing that makes Vraylar unaffordable, including patients in the Part D coverage gap. Note that Medicare patients cannot use the commercial copay card. Confirm eligibility for the assistance program through the official myAbbVie Assist website.

How long does it take to receive medication after approval?

After approval, the first shipment of Vraylar typically arrives at your physician’s office within a couple of weeks, though timelines vary. Subsequent refills are coordinated between your doctor’s office and AbbVie.

What if I get denied?

The denial letter will explain the reason — common causes include income above the threshold or having coverage deemed adequate. If your circumstances change, you can reapply. You can also explore other cost-reduction strategies in our healthcare costs guide.

Can my pharmacist apply on my behalf?

No. The application requires a prescribing physician’s signature and medical certification. Your pharmacist can provide information and help you locate the application, but the prescriber must complete their section.

Get the Help You Need

Managing schizophrenia, bipolar disorder, or major depressive disorder is hard enough without the added stress of unaffordable medication. The Vraylar Patient Assistance Program offers a genuine path to free medication for patients who meet the criteria, and the commercial copay card can help privately insured patients. Start by visiting the official myAbbVie Assist website and working with your psychiatrist to submit a complete package. Keep the boxed warnings in mind, never adjust an antipsychotic on your own, and reach out to 988 if you are ever in crisis. For more ways to manage your overall healthcare costs, explore our comprehensive guide.

Sources

• AbbVie / myAbbVie Assist (official patient assistance program) — eligibility criteria, income thresholds, covered products, and application steps; verify current terms on the official site
• FDA / DailyMed — Vraylar (cariprazine) prescribing information: boxed warnings and approved indications
• MedlinePlus (U.S. National Library of Medicine) — cariprazine consumer drug information
• CMS / Medicare.gov — Medicare Part D Extra Help (Low-Income Subsidy) and out-of-pocket rules
• 988 Suicide and Crisis Lifeline — free, confidential crisis support (call or text 988)